EMA Backs Breast Cancer SERD After FDA No Vote

by admin | May 22, 2026 | Health

Spread the love

The recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.
Medscape News Europe

← The Sweetener Trap: Are Sugar Alternatives Backfiring? EMA Backs First Drug for Severe Overgrowth Disorders →

Written By

Written by Albert Pham, News Curator and Blogger

McDonald’s Chicken and Beverage Strategy: Global Growth Plans Through 2030

Oct 12, 2026 | albertpham, Economy_finances, Health

McDonald’s is expanding its chicken menu and specialty beverages to gain market share by 2030, challenge competitors and attract more customers.

Endometriosis in Canada: Why Women Are Seeking Treatment in Mexico

Oct 12, 2026 | albertpham, Health, Travel

Canadian women are travelling to Mexico for endometriosis treatment after facing long wait times, highlighting gaps in specialist care and women’s health services.

Type 2 Diabetes Symptoms: 5 Early Warning Signs to Know

Oct 12, 2026 | albertpham, Health

Frequent thirst, fatigue, blurred vision and unexplained weight changes may signal type 2 diabetes. Learn the warning signs and when to seek medical advice.

EMA Backs Breast Cancer SERD After FDA No Vote

Written By

Related Posts

McDonald’s Chicken and Beverage Strategy: Global Growth Plans Through 2030

Endometriosis in Canada: Why Women Are Seeking Treatment in Mexico

Type 2 Diabetes Symptoms: 5 Early Warning Signs to Know

0 Comments

Explore More

Connect With Us

Quick Links

Legal

Stay Updated